jan 1, 2007 - Food and Drug Administration Amendments Act of 2007
Description:
Specifically authorized FDA to require manufacturers post-marketing clinical studies to monitor for risks infected during the pre-market approval process
Also required REMS programs where necessary. What is a REMS program?
Added to timeline:
Date: